N-MCT Conformational Locking for VZV Replication Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral drugs for shingles, caused by varicella-zoster virus (VZV), are not effective in halting the replication of the virus, leading to severe complications such as postherpetic neuralgia, which significantly impacts quality of life and incurs high healthcare costs.
Innovation Solution
Administration of N-methanocarbathymidine (N-MCT), a conformationally locked nucleoside analog, in various forms including oral, intravenous, topical, intramuscular, or subcutaneous routes, to effectively inhibit VZV replication and reduce the severity of shingles and its complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antiviral drugs are administered to treat shingles, then the treatment can be provided with current therapies, but the drugs are not effective in halting VZV replication and preventing severe complications
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of nucleoside analogs through conformational locking in the Northern configuration. This structural parameter change results in dramatically improved antiviral activity against VZV, with the locked nucleoside analog demonstrating potent inhibition of viral replication and prevention of complications like postherpetic neuralgia, thereby resolving the contradiction between current therapy availability and treatment effectiveness
2Reliability
If antiviral therapy is delayed after diagnosis, then treatment can still be provided, but the effectiveness in reducing pain severity and preventing complications decreases
Solution Approach 1:
The locked Northern conformation nucleoside analog is designed to be ready for immediate potent antiviral action upon administration. The pre-organized conformational structure allows the compound to immediately inhibit VZV replication without requiring metabolic activation or conformational adjustment, enabling effective treatment even when initiated after the optimal early window, thus mitigating the negative effects of treatment delay
3Reliability
If more effective antiviral drugs are developed, then the severity of complications can be reduced, but the complexity of drug development and approval increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying the conformational parameters of nucleoside analogs through the introduction of the methanocarba bridge. This single structural parameter change locks the sugar ring in the Northern conformation, resulting in dramatically enhanced antiviral activity against VZV. This focused structural modification approach provides a clear development pathway that balances improved efficacy with manageable development complexity
Data Source
AI summary
The present application discloses a method of treating a Varicella-Zoster Virus (VZV) infection in an individual in need thereof, including the step of administering to said individual an effective Varicella-Zoster Virus antiviral amount of a compound called N-methanocarbathymidine (N-MCT), which has a northern configuration with the structure as follows